Donald Notman Sells 6,301 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Donald Notman sold 6,301 shares of the business’s stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $7.84, for a total value of $49,399.84. Following the completion of the transaction, the insider now owns 204,563 shares in the company, valued at approximately $1,603,773.92. This trade represents a 2.99 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Donald Notman also recently made the following trade(s):

• On Tuesday, February 4th, Donald Notman sold 11,119 shares of Ocular Therapeutix stock. The stock was sold at an average price of $7.81, for a total value of $86,839.39.

Ocular Therapeutix Stock Performance

Shares of OCUL traded up $0.27 during midday trading on Tuesday, hitting $7.82. 904,622 shares of the stock traded hands, compared to its average volume of 904,992. The business’s 50 day moving average price is $8.61 and its two-hundred day moving average price is $9.02. The firm has a market capitalization of $1.23 billion, a PE ratio of -5.92 and a beta of 1.22. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01. Ocular Therapeutix, Inc. has a 1-year low of $4.06 and a 1-year high of $11.77.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Ocular Therapeutix by 146.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock valued at $9,661,000 after buying an additional 660,080 shares during the last quarter. Patient Square Capital LP acquired a new position in Ocular Therapeutix during the 3rd quarter worth $2,049,000. Polar Asset Management Partners Inc. acquired a new position in shares of Ocular Therapeutix during the third quarter valued at $4,288,000. SG Americas Securities LLC bought a new stake in shares of Ocular Therapeutix during the third quarter valued at about $393,000. Finally, FMR LLC lifted its holdings in Ocular Therapeutix by 7,098.7% in the third quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock worth $3,779,000 after purchasing an additional 428,335 shares during the period. 59.21% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on OCUL shares. HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. Scotiabank initiated coverage on shares of Ocular Therapeutix in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $22.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.71.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.